COVID-19 infection alters the microbes of the upper respiratory tract for at least several weeks, and such disturbances could impact disease severity and be targets for therapeutic interventions.

A high upper airway concentration of the virus that causes COVID-19 was associated with changes in gene expression that could impact disease progression, Vanderbilt researchers discovered.

A Vanderbilt research team has discovered that activation of a certain protein complex involved in the inflammatory response in immune cells contributes to salt-sensitive hypertension.

A technology developed at Vanderbilt has led to the discovery of an “ultra-potent” monoclonal antibody against multiple variants of SARS-CoV-2, the virus responsible for COVID-19, including the delta variant.

The U.S. Centers for Disease Control and Prevention (CDC) has awarded Vanderbilt University Medical Center a two-year, $3.7-million contract to determine genetic and bacterial factors that may increase the risk for severe illness and death from COVID-19.

Vanderbilt University Medical Center and the University of North Carolina (UNC) at Chapel Hill have been awarded $500,000 by Google’s philanthropy, Google.org, to study how COVID-19 alters gene expression in some people in ways that may be linked to their risk of severe illness and death.